



# Press Kit Almirall

2019

# Contents

## Almirall

---

<b>Who are we?</b>	<b>3</b>
Purpose	3
Corporate Values	3
Our Nobel Purpose	4
Strategic Direction	4
Business model	4
Major milestones	4
Almirall in figures	8
Corporate Operations	10

---

<b>Almirall &amp; you</b>	<b>11</b>
---------------------------	-----------

---

<b>Research &amp; Development</b>	<b>12</b>
Pipeline	13
Centres	13
AlmirallShare	15

---

<b>Our team</b>	<b>14</b>
-----------------	-----------

---

<b>Contact information</b>	<b>15</b>
----------------------------	-----------

# Who are we?

Almirall is a leading medical dermatology focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients & future generations. Our bet on medical dermatology addresses sustainable, granular unmet needs in well-defined patient and indication sub-groups.

The company, founded almost 75 years ago and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use Science to provide them with solutions for real life.

**"Because making Science useful is the essence of our work. We have a long history of empowering people to overcome challenges through it. At Almirall we feel the Science. We fight against skin health diseases."**

*Jorge Gallardo, Chairman and President of Almirall*

## Our Nobel Purpose

In 2019 we have defined our new Noble Purpose: **"Transform the patients' world by helping them realize their hopes & dreams for a healthy life"**, to reflect our reason why and our essence today and for future generations. This purpose transmits our goal to make our patient's life better, our focus on their wellbeing. It is our footprint, our legacy for future generations, and our contribution to society.

We have defined our purpose with the conviction that it will guide our strategy, leadership, culture and mindset towards the Business Success. It is our reason why, our essence. **Our daily work, our strategy as a company, our innovation and research**, all our small and big actions take us there, ultimately.

This purpose transmits **our goal to make our patient's life better**. Our focus on their wellbeing. We work hard every day to give them effective solutions but we also care and listen what they need.

**"This purpose is our footprint, our legacy for future generations. Our contribution to society. Now, it is time to embrace it, assimilate it, enjoy it and share it!"**

*Peter Guenter, CEO of Almirall*

## Corporate Values

Our values are the basis on which we are building a unique organization in which we feel empowered as key players in the evolution of the company. In 2017, we changed our corporate

image, defining values that have guided us towards a more agile, dynamic and collaborative culture to better achieve our business objectives. These values drive the Almirall team and inspire us to work diligently day after day to harness our knowledge and skills to find effective solutions and improve patients' quality of life.

### **Caring:**

- We always put the patients at the center
- We listen and empathize
- We help each other to succeed

### **Dedicated:**

- We are committed and passionate
- We are bold and accountable
- We never give up

### **Dynamic:**

- We are agile and keep things simple
- We empower entrepreneurial mindsets
- We challenge the status quo

### **Expert:**

- We dare to try and learn
- We are rigorous in everything we do
- We strive to always be one step ahead

## **Strategic Direction**

We have refocused our strategy on medical dermatology to best address patients' unmet needs. We invest in breakthrough innovation and substantially differentiated dermatology products to provide real solutions that make patients' lives better. And at **Almirall we believe that our work makes sense if we are faithful to our strategic direction:**

- We **double down on medical derma**, focusing on patient sub-populations, to address granular unmet needs.
- We capture **value through real differentiation**.
- BD and R&D efforts **targeting breakthrough innovation, with significant external collaboration**.
- We **"Play to win"**, investing in launch, M&A and capability building to maximize chances of success with an execution- focused culture.

## **Business model**

Almirall is focused in **medical dermatology**, which is an attractive segment in the **bio pharmaceutical industry**, as it is a very large growing market (20 billion sales and +15% growth) with high unmet needs. We have a wide range of medical solutions addressed to fight against skin health diseases, helping people feel better.

We know that it is important to **be bolder** in the field of innovation, both R&D and commercially to **maximize chances of success** and become an innovation leader in medical dermatology.

While maintaining our focus on medical dermatology, we complement our portfolio with other therapeutic divisions, such as central nervous system, cardiovascular and gastrointestinal, amongst others.

Almirall provides medical solutions and a product portfolio marketed through 13 affiliates, operating in 21 countries in Europe and the US. Our agreements with strategic partners in over 70 countries on the 5 continents also contribute to our global business model.

## Major milestones

- 1943** • Foundation of Laboratory Almirall, S.A.
- 1984** • Launch of gastroprokinetic clebopride in Spain, the first product of in-house research that is licensed abroad.
- 1979** • Launch of the antiacid almagate in Spain.
- 1985** • Launch of topical anti-inflammatory agent piketoprofen in Spain.
- 1990** • Launch of antihistamine ebastine and gastroprokinetic cinatipride in Spain.  
• Creation of the affiliate in Belgium.
- 1992** • Launch of anti-inflammatory aceclofenac in Spain.
- 1993** • Creation of the affiliate in Portugal.
- 1994** • Opening of the new Almirall headquarters in Barcelona, Spain.
- 1995** • Opening of the extended and remodeled Pharmaceutical Plant at Sant Andreu de la Barca (Barcelona, Spain).
- 1997** • Merger between Almirall and Prodesfarma.
- 2000** • Approval for commercialization of the anti-migraine almotriptan on behalf of the Food and Drug Administration (FDA) in the US. It is the first Spanish R&D medicine approved by the FDA.
- 2001** • Acquisition of the affiliate in France.
- 2002** • Creation of the affiliate in Italy.

- 2003**
  - Creation of the affiliate in Germany.
  
- 2005**
  - Almirall obtains commercial rights for Sativex® in Europe for the treatment of the spasticity associated to multiple sclerosis.
  
- 2006**
  - Official opening of the new R&D Centre in Sant Feliu de Llobregat (Barcelona, Spain).
  - Acquisition of the Inhaler Development Centre in Bad Homburg (Germany).
  
- 2007**
  - Almirall is listed on the Spanish Stock Exchange Market.
  - Acquisition of Hermal, a European prescription dermatology business of Reckitt Benckiser.
  - Acquisition of a portfolio of 8 products from Shire plc.
  
- 2008**
  - Opening of affiliates in Austria, Poland, Switzerland and the UK– Ireland.
  
- 2010**
  - Opening of affiliate in Nordic countries.
  
- 2011**
  - Launch of Actikerall® for the topic treatment of actinic keratosis.
  
- 2012**
  - Launch of acclidinium for the treatment of Chronic Obstructive Pulmonary Disease (COPD) in Europe marketed as Eklira® Genuair® and Bretaris® Genuair®. In US is marketed as Tudorza™ Pressair™. Launch of Monovo® for the treatment of inflammatory skin conditions like Psoriasis.
  
- 2013**
  - Acquisition of Aqua Pharmaceuticals, a US-based specialty dermatology Company.
  
- 2014**
  - Almirall transfers the rights of its respiratory franchise to AstraZeneca, including the development and commercialization of Almirall's existing proprietary respiratory business, the rights to revenues from Almirall's partnerships, as well as its pipeline of investigational novel therapies.
  - Acclidinium + formoterol combination approved in Europe.
  
- 2015**
  - First strategic partnership of Almirall in the area of aesthetics dermatology with the strategic investment in Suneva Medical.
  - Almirall acquires the rights to Veltin® and Altabax® from Stiefel, a GSK company, in exchange for its distribution rights to Toctino®.
  - Acquisition of Poli Group, a pharmaceutical company which specializes in dermatology, and is the world leader in nail diseases and treating conditions such as onychomycosis, nail psoriasis and nail dystrophy, skin fungal infections, rosacea and acne, among other specialties.
  
- 2016**
  - Almirall enters into the market of aesthetics through the acquisition of ThermiGen LLC, a company which leads the development of radio frequency technology solutions for aesthetics dermatology and plastic surgery.
  - Almirall signs a global licensing agreement with Patagonia Pharmaceuticals,

LLC. Acquiring the rights to develop and commercialize PAT-001, a new drug containing isotretinoin for the treatment of congenital ichthyosis together with any future dermatology indications.

- Almirall and Sun Pharmaceutical Industries Ltd. sign a licensing agreement for the development and commercialization of tildrakizumab within Europe, a novel biologic treatment for patients with moderate to severe plaque psoriasis.
- Almirall enters into a global strategic collaboration with Nuevolution, obtaining rights to their RORyt inhibitor program for inflammatory skin diseases as well as psoriatic arthritis.
- Almirall signs an exclusive collaboration agreement with Mercachem to identify and develop oral cytokine blockers, novel small molecule therapeutics for inflammatory skin diseases.

## 2017

- Almirall and Sun Pharma announced the validation of the Regulatory Filing of tildrakizumab with the European Medicines Agency (EMA), an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis.
- In March, Almirall enters the injectable facial filler market through a long-term development, technology license and supply agreement with Symatase. The development of a new range of hyaluronic acid facial fillers is the first step of this collaboration.
- Almirall and LEO Pharma revealed in May a unique collaboration in the field of dermatology that aims to advance understanding of skin diseases by setting a new standard for skin sampling.
- In June, the European Commission approved Skilarence<sup>®</sup>, a new oral formulation of dimethyl fumarate developed by Almirall, for the treatment for patients with moderate-to-severe chronic plaque psoriasis.
- Almirall launched Nano4Derm, a research project in collaboration with the Institute of Material Science of Barcelona from CSIC (ICMAB-CSIC), and Leitat Technology Center, focused in nanomedicine applied to treat dermatological diseases. Within this research project, new innovative formulations containing nanoencapsulated active ingredients will be developed for the topical treatment of inflammatory skin conditions, such as acne and psoriasis.
- In September, Almirall launched Skilarence<sup>®</sup> in Europe. The United Kingdom was the first country where this product was available, followed by Germany, Denmark, Sweden and Norway. This is Almirall's first product to go through the HTA process with the National Institute for Health and Care Excellence (NICE) and with this recommendation, suitable patient candidates will be able to receive this treatment.
- [AlmirallShare](#), an open innovation project, was unveiled at the middle of September. This platform is designed to facilitate the establishment of collaborations in dermatological research and find innovative solutions in skin health.
- In December, Almirall released a statement proclaiming an agreement with Athenex to further develop and commercialize KX2-391 in US and Europe for the treatment of actinic keratosis and other skin conditions.
- At the end of 2017, Almirall announced the execution of a license and supply agreement with AstraZeneca for Crestor<sup>®</sup> and Provisacor<sup>®</sup> (rosuvastatin) in Spain, both indicated as cholesterol-lowering treatments.

- In February, Almirall implemented an innovative photovoltaic installation in Sant Celoni (Barcelona) chemical plant.
- ThermiGen, an Almirall company, and Sinclair mutually agreed to terminate their collaboration on Silhouette Instalift™.
- In July, AlmirallShare launched Call 1, looking for advanced small molecules that could be used in the therapeutic treatment of dermatological diseases.
- Almirall, announced that both phase III studies of KX2-391 for actinic keratosis (AK) met the primary endpoint of complete clearance of actinic keratosis lesions at day 57 within the face or scalp treatment areas.
- Almirall received positive CHMP opinion for new anti-IL23 tildrakizumab for moderate to severe chronic plaque psoriasis.
- In August, Almirall entered an agreement to acquire 5 products of Allergan's U.S. medical dermatology portfolio for acne and dermatoses. It comprises a balanced portfolio of mature and growth brands, Aczone® (dapsons), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (fludroxycortide), as well as Seysara® (sarecycline), a new innovative first in class tetracycline-derived antibiotic with anti-inflammatory properties for the oral treatment of acne.
- In September, Almirall launched Skilerance® in Spain.
- Almirall and Evotec entered into a research collaboration focused on first-in-class therapies to treat dermatological diseases.
- The European Commission approved Almirall's Ilumetri® for moderate to severe plaque psoriasis (tildrakizumab), which marks Almirall's entry into the biological drugs market. It is due to be marketed in all EU Member states. Germany was the first country to launch it in Q4 2018.
- In September, Almirall closed an agreement to acquire Allergan's medical dermatology portfolio for acne and dermatoses.
- In October, the FDA approved Seysara™ (sarecycline), a New Chemical Entity for the treatment of inflammatory lesions of non-nodular moderate - to - severe acne vulgaris in patients 9 years of age and older. Seysara™ is the first oral antibiotic in 40 years that has been specifically designed for dermatology.
- [AlmirallShare](#) launched Call 2, looking for novel targets and concepts in the treatment of dermatological diseases.
- Almirall changed their subsidiary name in US from Aqua Pharmaceuticals to Almirall LLC.
- Almirall and the Barcelona Supercomputing Center signed a collaboration in SilicoDerm project focused on computational drug design applied to dermatological therapeutic targets.
- In November, Almirall launched AKASI App, an innovative calculator to assess actinic keratosis severity in the head.
- Almirall completed the construction of an innovative photovoltaic plant in Sant Andreu de la Barca (Barcelona) pharmaceutical plant.
- In December, Almirall and X-Chem signed a collaborative agreement to develop oral compounds for dermatological diseases.
- Almirall announced that the Phase III trial of P-3058 for onychomycosis achieved primary endpoint.



## 2019

- In January, Almirall announced the appointment of Francesca Domenech Wuttke as the new Chief Digital Officer and member of the Management Board of the company.
- The same month, Almirall's affiliate in the U.S., announced the launch of Seysara™ (sarecycline), the first therapy to be developed specifically for the treatment of acne.
- In February, Almirall, S.A announced the acquisition the option to exclusively license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe.
- In March, Almirall and HitGen announced that they will develop novel oral compounds in atopic dermatitis.
- Athenex and Almirall announced positive Topline Results from two phase III Studies of KX2-391 ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
- The first of April, FDA approved Duaklir® for chronic obstructive pulmonary disease.
- April 12<sup>th</sup> Almirall was recognized with the Distinguished Corporate Leadership award by the American Skin Association (ASA).
- In March, the NICE approved ILUMETRI® (Tildrakizumab), for treating adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

## Almirall in figures

### Company's ranking

- Almirall is the top dermatology prescription drug company in Germany, the 3rd in Europe\* and the 4th US\*\*.
- Medicines present in over 70 countries on the 5 continents.

\*Source: IMS Retail Sales € MAT Q4 18, EU5 markets, ATC Class "D" without biologics.

\*\* Source: IQVIA US SMART Retail Sales in \$ MAT Q4 18, ATC "D" includes only revenues from branded and branded generics. Excludes biologics, generics and O TC.

### Global outreach

- 13 affiliates located in Europe and US
- Operating in 21 countries
- Almirall products marketed in over 70 countries

### Employees

- 1,805 employees
- 269 people devoted to R&D – (15% of the staff)

### Total Revenues (2018)

- €811.0 MM

### Net Sales (2018)

- €756.9 MM

## Investment in R&D (2018)

- €87.6 MM → 11.6% of total Net Sales

## Breakdown of Almirall's 10 top-selling brands (2018)

Products	Proprietary/In-licensing	€ MM
Ebastel® and others (ebastine)	Proprietary	55
Tesavel® & Efficib® (sitagliptin)	In-licensing	49
Ciclopoli® (ciclopirox)	Proprietary	48
Crestor® (rosuvastatin calcium)	In-licensing	40
Solaraze® (diclofenac sodium)	In-licensing	34
Almax® (almagate)	Proprietary	29
Sativex® (tetrahydrocannabinol)	In-licensing	27
Decoderm® and others (fluprednidene)	Proprietary	26
Aczone® (dapson)	Proprietary	24
Airtal® franchise (aceclofenac)	Proprietary	23
Skilarence® (dimethyl fumarate)	Proprietary	18
Others	Proprietary / In-licensing	384
Total Net Sales		757

## Corporate Operations

Almirall's R&D is driven by three important principles: Science, Innovation, and Partnership. Our investment in R&D is fundamental to furthering our growth and pursuing our goal to cover the unmet needs of specialists and their patients.

We focus primarily on medical dermatology. However, we pursue acquisitions oriented towards increasing critical mass in key markets and in-licensing of late stage assets. Our strong financial position and our smart investment focus aligned with our corporate strategy will identify companies and/or assets in Europe and US, which generate shareholder value from the outset.

In 2018, we sharpened our focus on medical dermatology through a series of decisive mergers and acquisitions, licensing agreements, and collaborations. M&A is a priority and we are focused on scrutinising potential targets to secure a strong fit with our core business, whilst remaining financially disciplined and ensuring their proper operational integration. This approach allows us to maintain financial flexibility, while growing our leading dermatology franchise and creating shareholder value.

## **M&A Activities in 2018**

In August 2018, Almirall entered into a definitive agreement to acquire the former US medical dermatology portfolio from Allergan, an acquisition for a cash consideration of \$550 MM. Following this acquisition, we have established a more focused portfolio, consolidating medical dermatology portfolio and growing its presence in key geographies, such as the U.S.

This deal included a new chemical entity, Seysara™ (sarecycline), an innovative best-in-class tetracycline-derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. The Food & Drug Administration (FDA) approved Seysara™ in October 2018 based on the positive results of two identical Phase III registration studies. Seysara™ was launched in January 2019. We expect peak sales of Seysara™ from \$150 MM to \$200 MM. The portfolio also includes recognized brands in the US market, and includes Aczone® (dapson), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (fludrocortide).

## **Psoriasis franchise in Europe: Skilarence® and ILUMETRI®**

Europe is a key growth driver in medical dermatology, with Skilarence®, the first and only EU approved fumaric acid ester (FAE) for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis, generating strong sales in Germany and The Netherlands. It has been also launched in Spain and Italy, and will be launched in Portugal, Slovakia, Czech Republic and Belgium during 2019.

ILUMETRI® (tildrakizumab) is a humanized, high-affinity IL-23p19 monoclonal antibody, for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy. We started to market ILUMETRI® in Germany on November 2018, the first country to launch this biological therapy. ILUMETRI® is currently commercialized in UK and will be rolled out soon in other European countries.

## **Business Development**

Additional key business development operations include important collaborations established in 2018 that enhance the profitability and future prospects of our portfolio and pipeline.

In September 2018, **Almirall and Evotec** entered into a research collaboration to discover and develop first-in-class therapeutics through a novel approach to disrupt cell signaling, an agreement expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The collaboration combines Evotec's cutting-edge drug discovery and pre-clinical development platforms with Almirall's leading expertise in dermatology diseases.

In October 2018, **Almirall and the Barcelona Supercomputing Center** signed a collaboration in SilicoDerm project focused on computational drug design applied to dermatological therapeutic targets. The application of SilicoDerm computational methodologies will facilitate the identification of active compounds for the treatment of inflammatory skin diseases, specifically atopic dermatitis and psoriasis.

In December 2018, **Almirall and X-Chem, Inc.** started a collaboration for the development of oral compounds for patients suffering from dermatological diseases. X-Chem, Inc. is a privately held biotechnology company focused on applying its industry-leading DNA-encoded library (DEX™) drug discovery engine to the generation of novel small molecule therapeutics. This collaboration will enrich Almirall's R&D pipeline with the development of new solutions for patients with dermatological unmet medical needs.

Almirall and Athenex entered into a strategic partnership in December 2017 to further develop and commercialise ALM14789/KX2-391, a first-in-class dual Src kinase and tubulin polymerisation inhibitor in Phase III development as a topical medicinal product for the treatment of actinic keratosis and other skin conditions in the United States and Europe, including Russia. In July 2018, both Phase III ALM14789/KX2-391 studies for actinic keratosis (AK) met the primary endpoint of complete clearance of actinic keratosis lesions at day 57 within the face or scalp treatment areas, each study achieving statistical significance ( $p < 0.0001$ ) on this endpoint.

## Almirall & you

Almirall has the capacity to use Science to find solutions applied to the real world. Our strong commitment to our patients and our capacity to understand their goals and the answers they need, makes us different. We make our scientific knowledge available to others. We are determined that today's and future generations may enjoy health and wellness.

Almirall is a scientific company focused on medical dermatology, with a wide range of medical solutions. The skin is the largest organ of the body, covering a surface area of 2m<sup>2</sup>. It is the human body's first line of defense. It helps regulate body temperature and acts as a complex sensory organ. Through this understanding of Science, skin and the market, we have identified 9 diseases of interest in dermatology. With many skin diseases afflicting patients, we have carefully selected therapeutic areas where we know we can have the biggest impact and add the most value. This encompasses some of the more common illnesses, but also includes some extremely rare diseases currently lacking any effective treatment. Because of the extreme psychosocial burden and physical discomfort that many of these illnesses represent, our entire company is inspired to provide the widest possible array of treatment options. We work hand in hand with our customers in dermatology to make the Science they need to succeed available.

Almirall's activities in dermatology are concentrated on strategic brands such as Ilumetri® and Skilarence®, for moderate-to-severe plaque psoriasis; Solaraze® and Actikerall® for actinic keratosis; Balneum®, an emollient treatment designed for specific needs; Acticlate®/Monodox® for severe acne; Cordran® for steroid-respondent dermatoses; Xolegel® for seborrheic dermatitis; Verdeso® for atopic dermatitis; Decoderm® for the treatment of inflammatory or allergy-related skin diseases and Ciclopoli® for onychomycosis. Our dermatology portfolio was also boosted by the promising initial uptake of Veltin® and Altabax® since the US launch in July 2016, as well as a good performance of the products acquired from Polichem.



As we are a laboratory specialized in Science, our dermatology areas are completed with other innovative licensed drugs, such as Sativex® for spasticity in multiple sclerosis.

# Research & Development

As a Science-based company, R&D is fundamental to our long-term growth strategy, as we strive to enter the market with profoundly differentiated products that put patients' needs first. Looking towards the future, we will continue targeting our R&D investment with a proportional percentage of our Net Sales, in the range of 12%, as a catalyst for mid-to-long-term growth.

We are enriching our portfolio with a new medical dermatology strategy, based on an increasingly innovation driven model. We are actively looking for opportunities with the potential to put us in the right segments at the right time. There are significant medical unmet needs in attractive niches and in larger indications such as psoriasis and atopic dermatitis. Innovation—particularly as we increase our commitment to biologics—will contribute to double-digit growth in medical dermatology. Our strong knowledge of the dermatology market together with our solid portfolio, will maximise our chances of success and leadership.

Key therapeutic Indications



## Pipeline

Our pipeline is progressing as expected while we consolidate our focus on maturing it with true innovation coming from in-licensing and more long-term, in-house R&D. We have the capabilities and experience to manage all steps of the development process, the continued work with partners, and the ongoing learning of the regulatory procedures in both the EU and the US. We are proud of our team’s proactive and results-oriented way of working and partnering with others as we dedicate our efforts

to true

Program	Indication	Phase
<b>Sarecycline</b> (US brand name Seysara™) <b>Tildrakizumab</b> (EU brand name ILUMETRI®) <b>Dimethyl fumarate</b> (EU brand name Skilarence®)	Acne (oral) Psoriasis (biologic) Psoriasis (oral)	Registration
<b>ALM14789</b> <b>ALM12845</b> <b>ALM12834</b>	Actinic keratosis Androgenic alopecia Onychomycosis	Phase III
<b>ALM12734</b>	Psoriasis	Early development

innovation in medical dermatology

## AlmirallShare

AlmirallShare was launched in 2017 as an open innovation R&D platform designed to facilitate the establishment of collaborations in dermatological research and find innovative solutions in medical dermatology. By putting together Science and creativity of experts around the world and Almirall's own expertise, the AlmirallShare initiative will accelerate the generation of new treatments for skin conditions. We expanded its reach in 2018 with new calls for proposals. To date, more than **450 scientists** from all the continents have signed up to the platform and **over 170 proposals** have been received to date.

We have already established two exciting partnerships on preclinical models for atopic dermatitis with the University of Sheffield (UK) and University College Dublin (Ireland). Additional proposals received are being evaluated for potential strategic partnerships. On top of that, two biotech companies have been identified as new providers of state-of-the-art experimental models. Additional proposals selected from 2018 calls are currently being explored as new scientific collaborations.

## Centres

With two full R&D centres in Europe and one in the US dedicated to clinical and regulatory activities, Almirall has built and acquired the infrastructure needed to succeed in innovation.

In addition, two chemical plants (located in Sant Celoni and Sant Andreu) and two pharmaceutical plants (in Sant Andreu and Reinbek) produce our current products safely and efficiently; they are fully prepared for future launches, and provide the active ingredients needed for R&D toxicological, preclinical, and clinical studies. 56 million units of finished Almirall products are manufactured each year.

- **R&D Centre in Sant Feliú de Llogregat** (Barcelona, Spain). This is Almirall's flagship location with over 27,000 square metres dedicated to drug discovery, preclinical, clinical, and pharmaceutical development, with the capacity to develop new chemical entities. A large part of our R&D is conducted from bench to bedside at this cutting-edge centre, which opened in 2006, just outside Barcelona, and has 226 highly qualified employees.
- **R&D and Plant Centre in Reinbek** (Germany). With over 60 years of experience in formulations for dermatology, our experts at this facility work to find new topical treatments for skin diseases.
- **Exton, Pennsylvania (US)**. Almirall, LLC is our US-based specialty pharmaceutical company. We acquire, develop, and market dermatological treatments at this facility. It is the centre of our operations in the US, with a particular focus on clinical and regulatory activities.

## Our team

Almirall reaffirms its commitment to its team on a daily basis. Our goal is to encourage the professional development & talent of our employees. Additionally, we ensure and safeguard their health and safety in their day-to-day work.

We promote our culture and values through a variety of employee-centric initiatives and practices to provide our employees with the best possible working environment. A measure of our success in accomplishing this is the fact that the CRF Institute, an international organization that coordinates and publishes research projects in business, has rated Almirall as one of the Top Employers in Spain each consecutive year since 2008.

#### Demographic data

Total number of employees	1,805
Nationalities represented	26
Men	822 (46%)
Women	983 (54%)
Average seniority	13 years
Pharmaceutical industry experts	70%

## Contact Information



## Almirall

---

Communications Department

Pablo Divasson, **Head of Investor Relations and Corporate External Communications**

[pablo.divasson@almirall.com](mailto:pablo.divasson@almirall.com) Tel.: (+34) 93 291 30 87

Amaya Belacortu, **Corporate External Communications**

[amaya.belacortu@almirall.com](mailto:amaya.belacortu@almirall.com) Tel.: (+34) 93 291 30 96

## bcw

---

Marta Gállego – [marta.gallego@bcw-global.com](mailto:marta.gallego@bcw-global.com)

Adriana Ibarguen – [adriana.ibarguen@bcw-global.com](mailto:adriana.ibarguen@bcw-global.com)

Phone: (+34) 91 384 67 20